Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer

MA Inda; EJ Blok; PJK Kuppen; A Charehbili; EC den Biezen-Timmermans; A van Brussel; SE Fruytier; EMK Kranenbarg; S Kloet; B van der Burg; John Martens; AH Sims; AK Turnbull; JM Dixon; W Verhaegh; J R Kroep; CJH van de Velde; A Stolpe

doi:10.1158/1535-7163.Mct-19-0318

Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer

MA Inda, EJ Blok, PJK Kuppen, A Charehbili, EC den Biezen-Timmermans, A van Brussel, SE Fruytier, EMK Kranenbarg, S Kloet, B van der Burg, John Martens, AH Sims, AK Turnbull, JM Dixon, W Verhaegh, J R Kroep, CJH van de Velde, A Stolpe

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

26 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	680-689
Number of pages	10
Journal	Molecular Cancer Therapeutics
Volume	19
Issue number	2
DOIs	https://doi.org/10.1158/1535-7163.Mct-19-0318
Publication status	Published - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1535-7163.Mct-19-0318

Cite this

Inda, MA., Blok, EJ., Kuppen, PJK., Charehbili, A., den Biezen-Timmermans, EC., van Brussel, A., Fruytier, SE., Kranenbarg, EMK., Kloet, S., van der Burg, B., Martens, J., Sims, AH., Turnbull, AK., Dixon, JM., Verhaegh, W., Kroep, J. R., van de Velde, CJH., & Stolpe, A. (2020). Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer. Molecular Cancer Therapeutics, 19(2), 680-689. https://doi.org/10.1158/1535-7163.Mct-19-0318

@article{8886e19f9c204fd8ae6fc6e8a10e944e,

title = "Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer",

author = "MA Inda and EJ Blok and PJK Kuppen and A Charehbili and {den Biezen-Timmermans}, EC and {van Brussel}, A and SE Fruytier and EMK Kranenbarg and S Kloet and {van der Burg}, B and John Martens and AH Sims and AK Turnbull and JM Dixon and W Verhaegh and Kroep, {J R} and {van de Velde}, CJH and A Stolpe",

year = "2020",

doi = "10.1158/1535-7163.Mct-19-0318",

language = "Undefined/Unknown",

volume = "19",

pages = "680--689",

journal = "Molecular Cancer Therapeutics",

issn = "1535-7163",

publisher = "American Association for Cancer Research Inc.",

number = "2",

}

Inda, MA, Blok, EJ, Kuppen, PJK, Charehbili, A, den Biezen-Timmermans, EC, van Brussel, A, Fruytier, SE, Kranenbarg, EMK, Kloet, S, van der Burg, B, Martens, J, Sims, AH, Turnbull, AK, Dixon, JM, Verhaegh, W, Kroep, JR, van de Velde, CJH & Stolpe, A 2020, 'Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer', Molecular Cancer Therapeutics, vol. 19, no. 2, pp. 680-689. https://doi.org/10.1158/1535-7163.Mct-19-0318

TY - JOUR

T1 - Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer

AU - Inda, MA

AU - Blok, EJ

AU - Kuppen, PJK

AU - Charehbili, A

AU - den Biezen-Timmermans, EC

AU - van Brussel, A

AU - Fruytier, SE

AU - Kranenbarg, EMK

AU - Kloet, S

AU - van der Burg, B

AU - Martens, John

AU - Sims, AH

AU - Turnbull, AK

AU - Dixon, JM

AU - Verhaegh, W

AU - Kroep, J R

AU - van de Velde, CJH

AU - Stolpe, A

PY - 2020

Y1 - 2020

U2 - 10.1158/1535-7163.Mct-19-0318

DO - 10.1158/1535-7163.Mct-19-0318

M3 - Article

SN - 1535-7163

VL - 19

SP - 680

EP - 689

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

IS - 2

ER -